Inflammation and its associated immune response are involved in the initiation and maintenance of atrial fibrillation (AF)
AF can further promote inflammation, which contributes to the clinical phenomenon of 'AF begets AF'
Inflammatory pathways contribute to both electrical and structural atrial remodelling and thrombogenesis in patients with AF
The mechanisms and dynamic changes that underlie the inflammatory responses in different clinical scenarios of AF should be determined to enable the development of specific, individualized anti-inflammatory strategies
Therapies that target specific inflammatory cascades might be potential therapeutic strategies for the prevention of AF
Atrial fibrillation (AF) is the most common cardiac arrhythmia. However, the development of preventative therapies for AF has been disappointing. The infiltration of immune cells and proteins that mediate the inflammatory response in cardiac tissue and circulatory processes is associated with AF. Furthermore, the presence of inflammation in the heart or systemic circulation can predict the onset of AF and recurrence in the general population, as well as in patients after cardiac surgery, cardioversion, and catheter ablation. Mediators of the inflammatory response can alter atrial electrophysiology and structural substrates, thereby leading to increased vulnerability to AF. Inflammation also modulates calcium homeostasis and connexins, which are associated with triggers of AF and heterogeneous atrial conduction. Myolysis, cardiomyocyte apoptosis, and the activation of fibrotic pathways via fibroblasts, transforming growth factor-β and matrix metalloproteases are also mediated by inflammatory pathways, which can all contribute to structural remodelling of the atria. The development of thromboembolism, a detrimental complication of AF, is also associated with inflammatory activity. Understanding the complex pathophysiological processes and dynamic changes of AF-associated inflammation might help to identify specific anti-inflammatory strategies for the prevention of AF.
Your institute does not have access to this article
Open Access articles citing this article.
MicroRNA-205-5p plays a suppressive role in the high-fat diet-induced atrial fibrosis through regulation of the EHMT2/IGFBP3 axis
Genes & Nutrition Open Access 20 July 2022
Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation
BMC Medical Genomics Open Access 05 July 2022
Systemic immune inflammation index and system inflammation response index are potential biomarkers of atrial fibrillation among the patients presenting with ischemic stroke
European Journal of Medical Research Open Access 02 July 2022
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Camm, A. J. et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14, 1385–1413 (2012).
Chugh, S. S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129, 837–847 (2014).
Naccarelli, G. V., Varker, H., Lin, J. & Schulman, K. L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 104, 1534–1539 (2009).
January, C. T. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64, e1–e76 (2014).
Calkins, H. et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9, 632–696.e21 (2012).
Morillo, C. A. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 311, 692–700 (2014).
Calkins, H. et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm. Electrophysiol. 2, 349–361 (2009).
Guo, Y., Lip, G. Y. & Apostolakis, S. Inflammation in atrial fibrillation. J. Am. Coll. Cardiol. 60, 2263–2270 (2012).
Savelieva, I., Kakouros, N., Kourliouros, A. & Camm, A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13, 308–328 (2011).
Patel, P., Dokainish, H., Tsai, P. & Lakkis, N. Update on the association of inflammation and atrial fibrillation. J. Cardiovasc. Electrophysiol. 21, 1064–1070 (2010).
Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415–445 (2011).
Harrison, D. G. et al. Inflammation, immunity, and hypertension. Hypertension 57, 132–140 (2011).
Marzilli, M. et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J. Am. Coll. Cardiol. 60, 951–956 (2012).
Wang, T. J. et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292, 2471–2477 (2004).
Zacharias, A. et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 112, 3247–3255 (2005).
Lumeng, C. N., DelProposto, J. B., Westcott, D. J. & Saltiel, A. R. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 57, 3239–3246 (2008).
Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175–184 (2007).
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L. & Spiegelman, B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95, 2409–2415 (1995).
Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196–4200 (1997).
Mazurek, T. et al. Relation of proinflammatory activity of epicardial adipose tissue to the occurrence of atrial fibrillation. Am. J. Cardiol. 113, 1505–1508 (2014).
Nagashima, K. et al. Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ. Arrhythm. Electrophysiol. 5, 676–683 (2012).
Kanazawa, H. et al. Importance of pericardial fat in the formation of complex fractionated atrial electrogram region in atrial fibrillation. Int. J. Cardiol. 174 557–564 (2014).
Poirier, P. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113, 898–918 (2006).
Lau, D. H. et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm 7, 1282–1290 (2010).
Lau, D. H. et al. Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing. PLoS ONE 8, e72416 (2013).
Kistler, P. M. et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur. Heart J. 27, 3045–3056 (2006).
Friedrichs, K. et al. Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins. PLoS ONE 9 e89307 (2014).
Suzuki, Y. et al. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35, 881–900 (2003).
Wang, Y. et al. TNF-α and IL-1β neutralization ameliorates angiotensin II-induced cardiac damage in male mice. Endocrinology 155, 2677–2687 (2014).
De Jong, A. M. et al. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc. Res. 89, 754–765 (2011).
Zhang, J. et al. NOX4-dependent hydrogen peroxide overproduction in human atrial fibrillation and HL-1 atrial cells: relationship to hypertension. Front. Physiol. 3, 140 (2012).
Hori, M. & Nishida, K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 81, 457–464 (2009).
Sinno, H. et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107, 1930–1936 (2003).
Stellos, K. et al. Expression of platelet-bound stromal cell-derived factor-1 in patients with non-valvular atrial fibrillation and ischemic heart disease. J. Thromb. Haemost. 10, 49–55 (2012).
Mehta, N. N. et al. The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. Eur. Heart J. 32, 963–971 (2011).
Kim, D. et al. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia 57, 1456–1465 (2014).
Patti, G. et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114, 1455–1461 (2006).
Zhang, Z. et al. n-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int. J. Cardiol. 153, 14–20 (2011).
Ishii, Y. et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 111, 2881–2888 (2005).
Grubman, E. et al. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J. Cardiovasc. Electrophysiol. 10, 336–342 (1999).
Lim, H. S. et al. Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation. Circ. Arrhythm. Electrophysiol. 7, 83–89 (2014).
Richter, B. et al. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin. Res. Cardiol. 101, 217–225 (2012).
Mandal, K. et al. Association of anti-heat shock protein 65 antibodies with development of postoperative atrial fibrillation. Circulation 110, 2588–2590 (2004).
Li, H. et al. Atrial tachycardia provoked in the presence of activating autoantibodies to β2-adrenergic receptor in the rabbit. Heart Rhythm 10, 436–441 (2013).
Kornej, J. et al. Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation. J. Transl. Med. 11, 49 (2013).
Kato, K. et al. Genetic factors for lone atrial fibrillation. Int. J. Mol. Med. 19, 933–939 (2007).
Lin, H. et al. Targeted sequencing in candidate genes for atrial fibrillation: the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study. Heart Rhythm 11, 452–457 (2014).
Marcus, G. M. et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am. Heart J. 155, 303–309 (2008).
Gungor, B. et al. Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation. Pacing Clin. Electrophysiol. 36, 1220–1227 (2013).
Gaudino, M. et al. The −174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108 (Suppl. 1), II195–II199 (2003).
Chiang, C. H. et al. Herpes simplex virus infection and risk of atrial fibrillation: a nationwide study. Int. J. Cardiol. 164, 201–204 (2013).
Hsu, J. C. et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J. Am. Coll. Cardiol. 61, 2288–2295 (2013).
Yearley, J. H. et al. Antigenic stimulation in the simian model of HIV infection yields dilated cardiomyopathy through effects of TNFα. AIDS 22, 585–594 (2008).
Raidel, S. M. et al. Targeted myocardial transgenic expression of HIV tat causes cardiomyopathy and mitochondrial damage. Am. J. Physiol. Heart Circ. Physiol. 282, H1672–H1678 (2002).
Frustaci, A. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96, 1180–1184 (1997).
Boos, C. J., Anderson, R. A. & Lip, G. Y. Is atrial fibrillation an inflammatory disorder? Eur. Heart J. 27, 136–149 (2006).
Hu, Y. F. et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ. Arrhythm. Electrophysiol. 5, 334–340 (2012).
Jacob, K. A. et al. Inflammation in new-onset atrial fibrillation after cardiac surgery: a systematic review. Eur. J. Clin. Invest. 44, 402–428 (2014).
Smit, M. D. et al. Role of inflammation in early atrial fibrillation recurrence. Europace 14, 810–817 (2012).
Aviles, R. J. et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108, 3006–3010 (2003).
Marott, S. C. et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J. Am. Coll. Cardiol. 56, 789–795 (2010).
Conen, D. et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur. Heart J. 31, 1730–1736 (2010).
Dernellis, J. & Panaretou, M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. 25, 1100–1107 (2004).
Bruins, P. et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96, 3542–3548 (1997).
Ho, K. M. & Tan, J. A. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose–response meta-analysis. Circulation 119, 1853–1866 (2009).
Marcus, G. M. et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm 5, 215–221 (2008).
Marcus, G. M. et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 7, 149–154 (2010).
Chung, M. K. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104, 2886–2891 (2001).
Li, J. et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 7, 438–444 (2010).
Kallergis, E. M. et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 94, 200–204 (2008).
Rotter, M. et al. Decline in C-reactive protein after successful ablation of long-lasting persistent atrial fibrillation. J. Am. Coll. Cardiol. 47, 1231–1233 (2006).
Shiroshita-Takeshita, A., Brundel, B. J., Lavoie, J. & Nattel, S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc. Res. 69, 865–875 (2006).
Aime-Sempe, C. et al. Myocardial cell death in fibrillating and dilated human right atria. J. Am. Coll. Cardiol. 34, 1577–1586 (1999).
Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166–172 (2013).
Das, M. et al. Induction of hepatitis by JNK-mediated expression of TNF-α. Cell 136, 249–260 (2009).
Arslan, F., de Kleijn, D. P. & Pasterkamp, G. Innate immune signaling in cardiac ischemia. Nat. Rev. Cardiol. 8, 292–300 (2011).
Tousoulis, D. et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: the role of left atrium distension. Int. J. Cardiol. 136, 258–262 (2009).
Steiner, I. & Hajkova, P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc. Pathol. 15, 287–290 (2006).
Afzal, A. R. et al. Association of Met439Thr substitution in heat shock protein 70 gene with postoperative atrial fibrillation and serum HSP70 protein levels. Cardiology 110, 445–452 (2008).
Brundel, B. J. et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J. Mol. Cell. Cardiol. 41, 555–562 (2006).
Ichiki, H. et al. The role of infection in the development of non-valvular atrial fibrillation: up-regulation of Toll-like receptor 2 expression levels on monocytes. J. Cardiol. 53, 127–135 (2009).
Wang, J. et al. TLR2 was overexpressed independent of IL-6 in patients with valvular atrial fibrillation. J. Biomed. Res. 25, 178–184 (2011).
Katoh, S. et al. Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis. Heart Vessels 29, 263–272 (2014).
Boyd, J. H., Mathur, S., Wang, Y., Bateman, R. M. & Walley, K. R. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-κB dependent inflammatory response. Cardiovasc. Res. 72, 384–393 (2006).
Frangogiannis, N. G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 11, 255–265 (2014).
Monnerat-Cahli, G. et al. Toll-like receptor 4 activation promotes cardiac arrhythmias by decreasing the transient outward potassium current (Ito) through an IRF3-dependent and MyD88-independent pathway. J. Mol. Cell. Cardiol. 76, 116–125 (2014).
Yamashita, T. et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ. J. 74, 262–270 (2010).
Qu, Y. C. et al. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand. Cardiovasc. J. 43, 292–297 (2009).
Goette, A. et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117, 732–742 (2008).
Hu, Y. F. et al. Impact of circulating monocyte CD36 level on atrial fibrillation and subsequent catheter ablation. Heart Rhythm 8, 650–656 (2011).
Liu, L. et al. Activation of peripheral blood CD3+ T-lymphocytes in patients with atrial fibrillation. Int. Heart J. 53, 221–224 (2012).
Corradi, D. et al. Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. Heart Rhythm 11, 1250–1258 (2014).
Schuessler, R. B. et al. The effects of inflammation on heart rate and rhythm in a canine model of cardiac surgery. Heart Rhythm 9, 432–439 (2012).
Liao, C. H. et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J. Clin. Invest. 120, 242–253 (2010).
Gibson, P. H. et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am. J. Cardiol. 105, 186–191 (2010).
Canpolat, U. et al. Role of preablation neutrophil/lymphocyte ratio on outcomes of cryoballoon-based atrial fibrillation ablation. Am. J. Cardiol. 112, 513–519 (2013).
Guo, X. et al. Postablation neutrophil/lymphocyte ratio correlates with arrhythmia recurrence after catheter ablation of lone atrial fibrillation. Chin. Med. J. 127, 1033–1038 (2014).
Klebanoff, S. J. Myeloperoxidase. Proc. Assoc. Am. Physicians 111, 383–389 (1999).
Ishida, K. et al. Relation of inflammatory cytokines to atrial fibrillation after off-pump coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. 29, 501–505 (2006).
Stein, A. et al. Systemic inflammatory changes after pulmonary vein radiofrequency ablation do not alter stem cell mobilization. Europace 10, 444–449 (2008).
Kennedy, S., Wu, J., Wadsworth, R. M., Lawrence, C. E. & Maffia, P. Mast cells and vascular diseases. Pharmacol. Ther. 138, 53–65 (2013).
Chinetti-Gbaguidi, G., Colin, S. & Staels, B. Macrophage subsets in atherosclerosis. Nat. Rev. Cardiol. 12, 10–17 (2014).
Kared, H., Camous, X. & Larbi, A. T cells and their cytokines in persistent stimulation of the immune system. Curr. Opin. Immunol. 29, 79–85 (2014).
Schnabel, R. B. et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am. J. Cardiol. 104, 92–96 (2009).
Saba, S. et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am. J. Physiol. Heart Circ. Physiol. 289, H1456–H1467 (2005).
Sawaya, S. E. et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am. J. Physiol. Heart Circ. Physiol. 292, H1561–H1567 (2007).
Verheule, S. et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ. Res. 94, 1458–1465 (2004).
Choi, E. K. et al. Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1. Circ. J. 76, 1354–1362 (2012).
Wu, N. et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int. J. Cardiol. 169, 62–72 (2013).
Wang, Y., Hou, X. & Li, Y. Association between transforming growth factor β1 polymorphisms and atrial fibrillation in essential hypertensive subjects. J. Biomed. Sci. 17, 23 (2010).
Zhao, F. et al. Calreticulin overexpression correlates with integrin-α5 and transforming growth factor-β1 expression in the atria of patients with rheumatic valvular disease and atrial fibrillation. Int. J. Cardiol. 168, 2177–2185 (2013).
Nakatani, Y. et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J. Am. Coll. Cardiol. 61, 582–588 (2013).
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A. & Willerson, J. T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).
Rudolph, V. et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat. Med. 16, 470–474 (2010).
Li, S. B. et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J. Investig. Med. 61, 722–727 (2013).
Ghayour-Mobarhan, M., Saber, H. & Ferns, G. A. The potential role of heat shock protein 27 in cardiovascular disease. Clin. Chim. Acta 413, 15–24 (2012).
Brundel, B. J. et al. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovasc. Res. 78, 422–428 (2008).
Hoogstra-Berends, F. et al. Heat shock protein-inducing compounds as therapeutics to restore proteostasis in atrial fibrillation. Trends Cardiovasc. Med. 22, 62–68 (2012).
Yang, M. et al. Expression of heat shock proteins in myocardium of patients with atrial fibrillation. Cell Stress Chaperones 12, 142–150 (2007).
Brundel, B. J. et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ. Res. 99, 1394–1402 (2006).
Ke, L. et al. HSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced atrial myocytes. PLoS ONE 6, e20395 (2011).
Chang, S. L. et al. Heat shock protein inducer modifies arrhythmogenic substrate and inhibits atrial fibrillation in the failing heart. Int. J. Cardiol. 168, 4019–4026 (2013).
Wakisaka, O. et al. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J. Mol. Cell. Cardiol. 43, 616–626 (2007).
Schafler, A. E. et al. The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res. Cardiol. 97, 258–261 (2002).
De, A. K., Kodys, K. M., Yeh, B. S. & Miller-Graziano, C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-α induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J. Immunol. 165, 3951–3958 (2000).
Jin, C. et al. Human myocardium releases heat shock protein 27 (HSP27) after global ischemia: the proinflammatory effect of extracellular HSP27 through toll-like receptor (TLR)-2 and TLR4. Mol. Med. 20, 280–289 (2014).
Asea, A. et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277, 15028–15034 (2002).
Mathur, S., Walley, K. R., Wang, Y., Indrambarya, T. & Boyd, J. H. Extracellular heat shock protein 70 induces cardiomyocyte inflammation and contractile dysfunction via TLR2. Circ. J. 75, 2445–2452 (2011).
Lin, L. et al. HSP60 in heart failure: abnormal distribution and role in cardiac myocyte apoptosis. Am. J. Physiol. Heart Circ. Physiol. 293, H2238–H2247 (2007).
Kim, S. C. et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ. Res. 105, 1186–1195 (2009).
Tian, J. et al. Extracellular HSP60 induces inflammation through activating and up-regulating TLRs in cardiomyocytes. Cardiovasc. Res. 98, 391–401 (2013).
Kol, A., Lichtman, A. H., Finberg, R. W., Libby, P. & Kurt-Jones, E. A. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J. Immunol. 164, 13–17 (2000).
Zanin-Zhorov, A., Nussbaum, G., Franitza, S., Cohen, I. R. & Lider, O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J. 17, 1567–1569 (2003).
Rudolphi, U. et al. The B cell repertoire of patients with rheumatoid arthritis. II. Increased frequencies of IgG+ and IgA+ B cells specific for mycobacterial heat-shock protein 60 or human type II collagen in synovial fluid and tissue. Arthritis Rheum. 40, 1409–1419 (1997).
Schett, G. et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J. Clin. Invest. 96, 2569–2577 (1995).
Foteinos, G., Afzal, A. R., Mandal, K., Jahangiri, M. & Xu, Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 112, 1206–1213 (2005).
Gruden, G. et al. Anti-hsp60 and Anti-hsp70 antibody levels and micro/macrovascular complications in type 1 diabetes: the EURODIAB Study. J. Intern. Med. 266, 527–536 (2009).
van Puijvelde, G. H. et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 2677–2683 (2007).
Binder, C. J. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9, 736–743 (2003).
Cesena, F. H. et al. Immune-modulation by polyclonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE-/- mice. Atherosclerosis 220, 59–65 (2012).
Wakili, R., Voigt, N., Kaab, S., Dobrev, D. & Nattel, S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest. 121, 2955–2968 (2011).
Lee, S. H. et al. Tumor necrosis factor-α alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci. 80, 1806–1815 (2007).
Kao, Y. H. et al. Tumor necrosis factor-α decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit. Care Med. 38, 217–222 (2010).
Musa, H. et al. Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts. Heart Rhythm 10, 1044–1051 (2013).
Nelson, B. H. IL-2, regulatory T cells, and tolerance. J. Immunol. 172, 3983–3988 (2004).
Cao, C. M. et al. Influence of interleukin-2 on Ca2+ handling in rat ventricular myocytes. J. Mol. Cell. Cardiol. 35, 1491–1503 (2003).
Tselentakis, E. V., Woodford, E., Chandy, J., Gaudette, G. R. & Saltman, A. E. Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. J. Surg. Res. 135, 68–75 (2006).
Ryu, K. et al. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am. J. Physiol. Heart Circ. Physiol. 293, H1231–H1241 (2007).
Liew, R. et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ. J. 77, 1171–1179 (2013).
Lin, Y. J. et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am. J. Cardiol. 105, 495–501 (2010).
Wilhelm, M. et al. Inflammation and atrial remodeling after a mountain marathon. Scand. J. Med. Sci. Sports 24, 519–525 (2014).
Li, Y. Y. et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc. Natl Acad. Sci. USA 97, 12746–12751 (2000).
Burstein, B., Libby, E., Calderone, A. & Nattel, S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117, 1630–1641 (2008).
Psychari, S. N. et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am. J. Cardiol. 95, 764–767 (2005).
Luan, Y. et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace 12, 1713–1718 (2010).
Lip, G. Y., Patel, J. V., Hughes, E. & Hart, R. G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 38, 1229–1237 (2007).
Roldan, V. et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J. Thromb. Haemost. 10, 1500–1507 (2012).
Conway, D. S., Pearce, L. A., Chin, B. S., Hart, R. G. & Lip, G. Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107, 3141–3145 (2003).
Roldan, V. et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J. Am. Coll. Cardiol. 57, 2496–2504 (2011).
Chao, T. F. et al. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS ONE 8, e71675 (2013).
Nakamura, Y. et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb. Res. 111, 137–142 (2003).
Kaireviciute, D. et al. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J. Thromb. Haemost. 9, 2345–2352 (2011).
Fukuchi, M. et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J. Am. Coll. Cardiol. 37, 1436–1442 (2001).
Ito, K. et al. An immunohistochemical analysis of tissue thrombin expression in the human atria. PLoS ONE 8, e65817 (2013).
Marino, M. et al. Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets. J. Biol. Regul. Homeost. Agents 27, 841–852 (2013).
Conway, D. S., Buggins, P., Hughes, E. & Lip, G. Y. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am. J. Cardiol. 93, 1368–1373 (2004).
Hayashi, M. et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb. Res. 128, e113–e118 (2011).
Duygu, H. et al. Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation. Europace 10, 210–214 (2008).
Heeringa, J. et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999. J. Thromb. Haemost. 4, 1944–1949 (2006).
Savelieva, I., Kakouros, N., Kourliouros, A. & Camm, A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 13, 610–625 (2011).
Nigam, A. et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. J. Am. Coll. Cardiol. 64, 1441–1448 (2014).
Imazio, M. et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 124, 2290–2295 (2011).
Imazio, M. et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur. Heart J. 31, 2749–2754 (2010).
Deftereos, S. et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol. 60, 1790–1796 (2012).
Deftereos, S. et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm 11, 620–628 (2014).
Weis, F. et al. Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin-6 to interleukin-10 ratio and early outcome. Crit. Care Med. 37, 1685–1690 (2009).
Yared, J. P. et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J. Cardiothorac. Vasc. Anesth. 21, 68–75 (2007).
Andrade, J. G. et al. Corticosteroid use during pulmonary vein isolation is associated with a higher prevalence of dormant pulmonary vein conduction. Heart Rhythm 10, 1569–1575 (2013).
Koyama, T. et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J. Am. Coll. Cardiol. 56, 1463–1472 (2010).
Cappabianca, G., Rotunno, C., de Luca Tupputi Schinosa, L., Ranieri, V. M. & Paparella, D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J. Cardiothorac. Vasc. Anesth. 25, 156–165 (2011).
Won, H. et al. Effect of a single bolus injection of low-dose hydrocortisone for prevention of atrial fibrillation recurrence after radiofrequency catheter ablation. Circ. J. 77, 53–59 (2013).
Cappato, R. et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3, 32–38 (2010).
Themistoclakis, S. et al. Prospective European Survey on atrial fibrillation ablation: clinical characteristics of patients and ablation strategies used in different countries. J. Cardiovasc. Electrophysiol. 25, 1074–1081 (2014).
Kleinbongard, P., Schulz, R. & Heusch, G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail. Rev. 16, 49–69 (2011).
Price, J. V. et al. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J. Clin. Invest. 123, 5135–5145 (2013).
Marik, P. E. & Fromm, R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. J. Crit. Care 24, 458–463 (2009).
Allessie, M. A. et al. Pathophysiology and prevention of atrial fibrillation. Circulation 103, 769–777 (2001).
Kaireviciute, D. et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb. Haemost. 104, 122–127 (2010).
Rudd, J. H. et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J. Am. Coll. Cardiol. 55, 2527–2535 (2010).
Wu, C. H. et al. Transforming growth factor-β1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Heart Rhythm 10, 10–15 (2013).
Leftheriotis, D. I. et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int. J. Cardiol. 135, 361–369 (2009).
Cao, H. et al. Heat shock proteins in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cell Stress Chaperones 16, 517–528 (2011).
Schafler, A. E., Hannekum, A. & Kirmanoglou, K. Unchanged heat-shock protein 70 expression in myocardium of patients with permanent atrial fibrillation. J. Cardiovasc. Surg. 51, 923–927 (2010).
Mandal, K. et al. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann. Thorac. Surg. 79, 865–871 (2005).
St. Rammos, K. et al. Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc. Surg. 10, 228–232 (2002).
Parthenakis, F. I. et al. Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy. Int. J. Cardiol. 118, 206–214 (2007).
Wang, H. et al. Increased serum levels of microvesicles in nonvalvular atrial fibrillation determinated by ELISA using a specific monoclonal antibody AD-1. Clin. Chim. Acta 411, 1700–1704 (2010).
Hak, L. et al. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J. Interferon Cytokine Res. 29, 327–332 (2009).
Rizos, I. et al. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine 40, 157–164 (2007).
Henningsen, K. M. et al. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand. Cardiovasc. J. 43, 285–291 (2009).
Henningsen, K. M. et al. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand. J. Clin. Lab. Invest. 69, 425–432 (2009).
Liuba, I. et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 10, 848–853 (2008).
Wu, Z. K. et al. High postoperative interleukin-8 levels related to atrial fibrillation in patients undergoing coronary artery bypass surgery. World J. Surg. 32, 2643–2649 (2008).
De Gennaro, L. et al. Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur. J. Clin. Invest. 42, 371–375 (2012).
Nakano, Y. et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J. Am. Coll. Cardiol. 43, 818–825 (2004).
Kim, S. K. et al. Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Korean Circ. J. 40, 185–190 (2010).
Rosenberg, M. A. et al. Circulating fibrosis biomarkers and risk of atrial fibrillation: the Cardiovascular Health Study (CHS). Am. Heart J. 167, 723–728.e2 (2014).
Kimura, T. et al. Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. Heart Lung Circ. 23, 636–643 (2014).
This authors were supported in part by the Ministry of Science and Technology, Taiwan (NSC102-2325-B-010-005, NSC-101-2321-B-075–004, and NSC102-2911-I-008-001).
The authors declare no competing financial interests.
About this article
Cite this article
Hu, YF., Chen, YJ., Lin, YJ. et al. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 12, 230–243 (2015). https://doi.org/10.1038/nrcardio.2015.2
MicroRNA-205-5p plays a suppressive role in the high-fat diet-induced atrial fibrosis through regulation of the EHMT2/IGFBP3 axis
Genes & Nutrition (2022)
Analysis of potential genetic biomarkers using machine learning methods and immune infiltration regulatory mechanisms underlying atrial fibrillation
BMC Medical Genomics (2022)
BMC Cardiovascular Disorders (2022)
Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation
BMC Medical Genomics (2022)
Causal associations of circulating adiponectin with cardiometabolic diseases and osteoporotic fracture
Scientific Reports (2022)